Skip to content

OxSonics Therapeutics Contact us We want to hear from you

SonoTran^® Platform
Development Pipeline
Partnering
Scientific Publications

Home
About us
News, Media & Events
Careers
Contact

Ultrasound-enhanced delivery and improved efficacy of an oncolytic Vaccinia virus in a murine bladder cancer model

Ultrasound-enhanced delivery and improved efficacy of an oncolytic Vaccinia virus in a murine bladder cancer model

Ultrasound-enhanced delivery and improved efficacy of an oncolytic Vaccinia virus in a murine bladder cancer model

25 October 2022

Caring is sharing

Share on Facebook
Share on Twitter
Share on LinkedIn
Share by email

© 2024 OxSonics. All rights reserved

Legal Information

thinkerdoer

Intellectual property

OxSonics' proprietary IP portfolio

OxSonics’ proprietary intellectual property portfolio consists of multiple patent families and a substantial body of know-how that collectively provide protection to several key elements of the SonoTran^® Platform.

Patents protecting OxSonics core technology have been granted across key jurisdictions with several further patents at an advanced stage of prosecution.

Contact us